Clinical Observation of Meglumine Adenosine Cyclophosphate in the Treatment of Acute Myocardium In-farction
10.6039/j.issn.1001-0408.2017.23.30
- VernacularTitle:环磷腺苷葡胺治疗急性心肌梗死的临床观察
- Author:
Shujie TANG
;
Jiuguang QIAN
;
Xuwei ZHAO
;
Yang LIU
;
Jiaqi ZHANG
;
Zicheng WANG
- Keywords:
Meglumine adenosine cyclophosphate;
Acute myocardium infarction;
hs-CRP;
NT-proBNP
- From:
China Pharmacy
2017;28(23):3274-3276
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate clinical efficacy and safety of meglumine adenosine cyclophosphate in the treatment of acute myocardium infarction. METHODS:A total of 80 patients with acute myocardium infarction in our hospital during May 2015-Jan. 2016 were selected and divided into control group and observation group according to random number table,40 cases in each group. Control group was given conventional treatment. Observation group was additionally given Meglumine adenosine cyclo-phosphate injection 120 mg added into 5% Glucose injection 250 mL,ivgtt,qd,on the basis of control group. Both groups re-ceived treatment for 7 d. Clinical efficacies as well as the levels of serum hs-CRP and NT-proBNP before and after treatment were observed in 2 groups,and the occurrence of ADR was compared between 2 groups. RESULTS:Total response rate of observation group(92.50%)was significantly higher than that of control group(75.00%),with statistical significance(P<0.05). Before treat-ment,there was no statistical significance in the serum levels of hs-CRP or NT-proBNP between 2 groups(P>0.05). After treat-ment,the serum levels of hs-CRP and NT-proBNP in 2 groups were decreased significantly,and the observation group was signifi-cantly lower than the control group,with statistical significance(P<0.05). There was no statistical significance in the incidence of ADR between 2 groups(P>0.05). CONCLUSIONS:Meglumine adenosine cyclophosphate shows significant therapeutic efficacy for acute myocardium infarction,reduces serum levels of hs-CRP and NT-proBNP significantly with good safety.
